About Us

Multitude of research reports are published every year to provide business intelligence to investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and academia. These research reports use methodology that may bear fair relevance to equity analysis of established companies with tangible assets. They may also project growth of developed or growing markets with fair accuracy. But in reference to companies that are still wrestling with novel unproven technologies, and in terms of future technology-dependant markets that do not exist today, such reports are mostly inadequate.

MetaReports.net offers a unique propreitary methodology that eliminates all biases and exceeds all measures of neutrality in presenting a most exhaustive analysis of the potential intellectual properties that are foundations on which all future equity or market analysis depends. MetaReports provide a powerful tool for business planners, investors and investor consultants, acquisitions specialists, licensing strategists, product managers, market research analysts, expert committees, regulatory approval committees, academicians and beneficiaries involved and interested in the researched subject matter.

Neo-Cardiogenesis– Celebrating The Birth Of Regenerative Cardiology

CAT No.MRCS-01

About This MetaReport: Regenerative cardiology is a segment of one of the most heavily funded areas of medical research in human history. The initial euphoria of growing natural bypass to the blocked coronary arteries was dampened by the ghost of “placebo-effect” that resulted in less than desirable outcomes of the first wave of clinical trials. In its Second Coming the drug development industry is back with a vengeance to conquer the eluding dream. The rush to get a non-invasive heart repair drug is unprecedented. Despite no sign of success in any of the dozens of clinical trials already reported, we account for more than 80 companies in pursuit of the promised heart mender. Such a scale of drug development initiative for a single category of indication has no parallel or precedence in healthcare industry. It’s nothing less than the Gold Rush of 21st Century.

Although this research was intended as purely a “regenerative cardiology market analysis and business intelligence report”, the technology leaning of our research team in serendipity, discovered a breakthrough that will not only revitalize the currently active or on-hold neocardiogenesis programs, but also hold out a promise to revive and salvage hundreds of millions of dollars invested in those programs that were terminated for reasons of insufficient or no efficacy. This project culminated in at least three patents either filed or under preparation. The report, for the first time, identifies unique problems facing the neocardiogenesis clinical trials, and prepares the biotechnology industry for the Second Coming of regenerative cardiology.

Free Preview:        Cover   |  Table Of Content  |  Executive Summary  |  Excerpts  |  Companies Profiled
What is Neo-Cardiogenesis?
Home |  FAQ |  Contact Us |  Terms & Conditions |  Disclaimer                  ©, 2008. All Rights Reserved.